Press Release

Australian patent accepted for Materialise’s 3D planning technologies and 3D-printed guides enabling the desired fixation of personalized implants

Leuven, Belgium – June 19, 2018. Materialise NV (NASDAQ: MTLS) is a world leader in the development of technology enabling personalized healthcare solutions. Materialise’s latest patent, accepted by the Australian Patent Office, concerns Materialise’s 3D planning technologies and 3D-printed guides which enable the design of screw placements for the fit and fixation of customized implants. With the recent expansion of its portfolio of medical patents, Materialise continues to strengthen its unique position in the healthcare industry, supporting its commitment to help patients worldwide through technological innovation.

With over 20 years of experience in medical 3D Printing and planning, and a significant IP portfolio of 160 granted medical patents, Materialise is in a unique position to support surgeons with planning tools and personalized medical devices for complex patient cases. The latest addition to the portfolio in Australia strengthens the company’s expertise in personalized implant development, in particular Materialise’s 3D planning technologies and 3D printed guides that allow the accurate planning and design of screw placements for customized implants, ensuring the desired fixation and bone preservation.

Materialise has been transforming the field of personalized medicine for years, providing a full spectrum of personalized solutions for surgeons and hospitals, including 3D-printed guides, which surgeons use to perform highly accurate cutting and drilling during surgery, as well as 3D-printed implants and pre-surgical planning software. Complex cases, such as when a patient undergoes cranio-maxillofacial surgeries to correct deformities or traumas, or when a patient suffers from a complex congenital heart  condition where surgeons need to plan the surgery in 3D beforehand, can sometimes only be helped with a personalized solution.

Materialise CEO Fried Vancraen states, “Materialise has always been dedicated to improving patient outcomes through our technological advancements and innovations, and this is underscored by a strong IP portfolio which we are continuously building upon. This patent, which has already been granted in other countries, is of great importance to Materialise. It protects key technological features that enable the treatment of patients with severe joint problems in the hip with a documented close to 100% success rate. We are extremely proud to be able to help people in their search to regain mobility.”

With a presence in Australia since 2007, Materialise is committed to expanding new and innovative technology together with local surgeons in the field of healthcare.

About Materialise

Materialise incorporates over 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

Press Contacts:

Bram Smits, Materialise HQ
bram.smits@materialise.be

Phone: +32 16744987
 Email: Press@materialise.com
 Twitter: @MaterialiseNV
 Visit: www.materialise.com

Australian Contact:

Madeleine McIntyre, Materialise Australia
Madeleine.Mcintyre@materialise.be
Phone: +61 2 8458 3343

Cautionary Statement on Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.